Clinical Trial Update: A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating XMT-2056 in HER2-expressing advanced or recurrent solid tumors; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Gastric Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• XMT-2056

Snippet

Sponsor: Mersana Therapeutics | Conditions: HER2-positive Breast Cancer, HER2-positive Gastric Cancer | Phase 1 | Status: RECRUITING